Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania

The Lancet

Volumn 344, Issue 8931, 1994, Pages 1175-1181

  Teuscher, T ^a   Masanja, H ^a   Bastos de Azevedo, I ^a   Mwankusye, S ^a   Kobero, S ^a   Urassa, H ^a   Lyimo, E ^a   Chongela, J ^a   Kitua, A Y ^a   Kilama, W ^a   Alonso, P L ^b   Menendez, C ^b   Thomas, M C ^c   Lopez, M C ^c   Armstrong Schellenberg, J R M ^d   Hayes, R ^d   Smith, T ^e   Weiss, N ^e   Tanner, M ^e  

^a NATIONAL INSTITUTE OF MEDICAL RESEARCH   (Tanzania)

^b HOSPITAL CLÍNIC   (Spain)

^c INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; FANSIDAR; MALARIA VACCINE; POLYPEPTIDE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE TRANSMISSION; DOUBLE BLIND PROCEDURE; ERYTHEMA; ERYTHROCYTE; FEMALE; FEVER; FOLLOW UP; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALARIA; MALE; MORBIDITY; PARASITEMIA; PHASE 3 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; STATISTICAL ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TANZANIA;

EID: 0027984492     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(94)90505-3     Document Type: Article

References (25)

1. Malaria how much is there worldwide?
2. Is the acquired homologous immunity to Plasmodium vivax equally effective against sporozoites and trophozoites?
3. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites
4. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine
5. Safety, immunogenicity and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A
6. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites
7. Development of an asexual blood stage malaria vaccine
8. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum.
9. The first field trial of the chemically synthezised malaria vaccine SPf66: safety, immunogenicity and protectivity
10. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia
11. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela
12. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against P falciparum infection in a randomized double blind placebo controlled field trial in an endemic area in Ecuador
13. SPf66, a chemically synthesized subunit malaria vaccine is safe and immunogenic in Tanzanians exposed to intense malaria transmission
14. A trial of SPf66 a synthetic malaria vaccine in Kilombero (Tanzania) rationale and design
15. Morbidity and mortality at Kilombero, Tanzania, 1982-88
16. Absence of seasonal variation in malaria parasitaemia in an area of intense seasonal transmission
17. In vitro resistance patterns of Plasmodium falciparum to chloroquine: a reflection of strain specific immunity?
18. Characterization of SPf(66)n: a chimeric molecule used as a malaria vaccine
19. Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria
20. The microscopic diagonisis of malaria
21. Quantitative determination of chloroquine and desethyl-chloroquine in biological fluids by high performance thin-layer-chromatography
22. What is clinical malaria? Finding case definitions for field research in highly endemic areas